Cardiology

In part 2 of an interview with HCPLive, Ty Gluckman, MD discusses both the advantages and disadvantages of technology replacing traditional care.

Marc Bonaca, MD discusses the personalization of treatment in PAD patients, lack of proper research into the condition, and optimizing delivery of care.

Advancements in technology and the availability of resources for patients and doctors alike could mean a bright future for cardiology research.

Ty Gluckman, MD speaks on the use of medical technology, including wearables and and telemedicine, and the growing importance of mobile health.

Harold Bays, MD discussed the effectiveness of GLP-1 RA in treatment, as well as the development of oral semaglutide.

Dr. Taub speaks on the technology-based advancements in cardiovascular care and socioeconomic status can affect a patient’s diet and access to care.

Peter Toth, MD discusses the combination treatment aspects of lipid management agents, as well as the effect of the COVID-19 pandemic on cardiovascular care.

Dr. Pam Taub speaks on the misconceptions of cardiac rehabilitation and other lifestyle approaches recommended for patients with cardiovascular diseases.

Peter Toth, MD, discusses the movement towards new agents in treatment of lipid management.

Martha Gulati, MD, discusses nutrition and its role in preventive cardiology as well as other highlights from the American Society for Preventive Cardiology's 2021 Virtual Summit.

New guidelines on aortic valve implantation in risk groups with aortic stenosis shifted from risk strata to a focus on patient age and life expectancy.

Analysis of more than 18 million pregnancies sheds light on the impact various prepregnancy cardiovascular risk factors, including BMI, smoking status, and diabetes, can have on risk of adverse maternal and fetal outcomes.

In his most recent column, Dr. Paul Thompson offers perspective on why he feels clinicians should consider performing a chest x-ray in patients with dyspnea or frequent palpitations, but no history of lung disease and a normal cardiac work-up.

Data show a significant association between wearable tracker use and increased physical activity during a 15-week period.

A recent study has found statins are underutilized for NASH and NAFLD patients.

A prespecified analysis of patients with stage 4 CKD from DAPA-CKD suggests the magnitude of effects seen with dapagliflozin use among these patients was similar to that seen among patients with normal to moderately impaired kidney function from the trial.

Data show postoperative initiation of factor XI inhibition was effective method for reducing the risk of VTE following total knee arthroplasty.

A 412-patient trial comparing 3 dosing regimens of abelacimab versus enoxaparin, results indicate all 3 regimens of abelacimab demonstrated noninferiority against enoxaparin and 2 of the 3 demonstrated superiority against the current standard of care.

The FDA's CRDAC July 15 meeting concluded with committee members voting against recommending the approval of roxadustat for the treatment of anemia in adult patients with chronic kidney disease not on dialysis and on dialysis.

A 10-year study presented at the European Association of Urology meeting indicates testosterone therapy was associated with a decreased risk of major adverse cardiovascular events in men with hypogonadism.

The subject of a July 15 meeting, the FDA's Cardiovascular and Renal Drugs Advisory Committee voted 13-1 and 12-2 against recommending approval of roxadustat for treatment of anemia in adult patients with chronic kidney disease not on dialysis and on dialysis, respectively.

The FDA Cardiovascular and Renal Drugs Advisory Committee cited concerns over an increase in thrombotic events.

A new statement from the AHA and American Stroke Association stressed the need to address gaps in care that may lead to high risk of stroke recurrence.

Data show both microvascular and macrovascular outcomes were significantly improved following bariatric intervention in patients with obesity.

In his latest column, Dr. Paul Thompson offers perspective on the diagnosis and potential overdiagnosis of non-compaction cardiomyopathy in athletes.